Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. administers 462.3 mln doses of COVID-19 vaccines - CDC

12/01/2021 | 05:44pm EST

Dec 1 (Reuters) - The United States has administered 462,263,845 doses of COVID-19 vaccines in the country as of Wednesday morning and distributed 575,721,925 doses, the U.S. Centers for Disease Control and Prevention said.

Those figures are up from the 460,773,508 vaccine doses the CDC said had gone into arms by Nov. 30 out of 573,238,255 doses delivered.

The agency said 233,590,555 people had received at least one dose while 197,363,116 people are fully vaccinated as of 6:00 a.m. ET on Wednesday.

The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech , as well as Johnson & Johnson's one-shot vaccine.

About 41.9 million people received a booster dose of COVID-19 vaccine from either Pfizer or Moderna or J&J. Booster doses from Moderna and Johnson & Johnson were authorized by the U.S. health regulator on Oct. 20. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)


ę Reuters 2021
All news about MODERNA, INC.
09:38aModerna, IAVI Say Clinical Trial of Experimental HIV Vaccine Antigens is Underway
MT
09:19aMODERNA : IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Tec..
PU
09:09aWALL STREET STOCK EXCHANGE : Are we still in the Goldilocks zone?
08:57aMARKETSCREENER'S WORLD PRESS REVIEW : January 27, 2022
01/26Pfizer-BioNTech, Moderna COVID-19 Jabs Shown Safe For Women Undergoing IVF in Study
MT
01/26Moderna Launches Mid-Stage Study of Omicron-Specific Booster Jab
MT
01/26Moderna starts trial for Omicron-specific booster shot
RE
01/26Moderna starts trial testing Omicron-specific booster shot
RE
01/26MODERNA : Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster C..
PU
01/26Moderna begins testing omicron-matched COVID shots in adults
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 769 M - -
Net income 2021 11 260 M - -
Net cash 2021 11 938 M - -
P/E ratio 2021 5,83x
Yield 2021 -
Capitalization 62 828 M 62 828 M -
EV / Sales 2021 2,86x
EV / Sales 2022 1,85x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 154,96 $
Average target price 265,41 $
Spread / Average Target 71,3%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601
CELLTRION, INC.-21.21%18 165